$FOCL

Mobeck Kenneth S. purchased $24K of FOCL

Mobeck Kenneth S. (Chief Financial Officer) purchased 5,000 shares of EDAP TMS SA (FOCL) at $4.75 on 2026-08-14.

Original reporting
SEC EDGAR · Mobeck Kenneth S.
Published Aug 17, 2026, 10:02 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FOCL
Neutral
low confidence
Mentioned
$FOCL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FOCLNeutralLow
01

Why it matters

The newest disclosed fact is the CFO’s open-market purchase of 5,000 shares at $4.75, without a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider buying, but the filing lacks any fundamental catalyst, so it is unlikely to drive a major repricing by itself.

03

What to watch

The transaction size is relatively small ($23,750) and the article provides no context on prior insider activity or any concurrent corporate news.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for EDAP TMS SA (FOCL).

Company-level read

Ticker impact

$FOCLNeutralLow confidence
Context

SEC Form 4 shows CFO Mobeck Kenneth S. bought 5,000 shares of FOCL at $4.75 on 2026-08-14, totaling $23,750.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 insider transaction, with no 10b5-1 plan and no accompanying company-specific catalyst or guidance change in the text.

Market effects

No sector-level implications are disclosed; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by diversification, liquidity needs, or routine compensation-related behavior, so the signal may be weak.

Key entities

  • EDAP TMS SA

    Company subject of the Form 4 insider transaction disclosure.

  • Mobeck Kenneth S.

    Chief Financial Officer who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

$FOCLMed

FocalTherics Q2 Earnings Call Highlights

FocalTherics (NASDAQ:FOCL) reported Q2 highlights from its earnings call. U.S. Focal One procedure volumes rose 47% YoY. HIFU gross margin increased to 55.6% from 51.1%. Cash was $21.5M and it drew about €14M under its EIB credit facility. The company plans a $40M Aug. 14 offering and reiterated 2026 HIFU revenue guidance of $50M to $54M.

$FOCLMedAI 8/10

FocalTherics Reports Q2 2026 Revenue of $13.2M; Net Loss $14.5M

FocalTherics (FOCL) reported Q2 2026 continuing-operations revenue of $13.2M, up 39% year over year, with gross profit of $7.3M and 55.6% gross margin. Net loss was $14.5M, or $0.39 per share. Cash was $21.5M at June 30, 2026. The company also announced an underwritten public offering for about $40M expected to close Aug. 14, 2026.

$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial resul

$FOCLMed

FocalTherics Reports Preliminary Q2 2026 Results, Announces $40 Million Offering; Stock Down

FocalTherics (FOCL) reported preliminary unaudited Q2 2026 results. Revenue is expected at $12.7 to $13.2 million, up 34% to 39% from $9.7 million in Q2 2025, with gross margin at 54% to 56% versus 42.5%. Cash and investments were $21.5 million as of June 30. The company priced a public offering of 8.425M ADS at $4.75 to raise about $40M gross, with an option for 1.26375M more ADS.

$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, August 11, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Com